EN
Open the app
Get the AIsier app Get it on Google Play

Drug Research & Approvals

Major drug-trial readouts and regulator decisions (GLP-1 era): results can re-rate a drugmaker for years in either direction, while competitors and related sectors (food, medtech) reprice.

Asset classes: Stocks, Funds · Sectors: Healthcare

Dated events

  1. · Pfizer and BioNTech report their COVID-19 vaccine was more than 90% effective in a Phase 3 interim analysis
    The first interim look at the 43,538-person trial, based on 94 confirmed cases, found the vaccine more than 90% effective; the companies planned to ask the FDA for emergency use authorization.
  2. · FDA approves Novo Nordisk's Wegovy (semaglutide 2.4 mg) for chronic weight management
    It was the first once-weekly GLP-1 therapy approved for weight management; in the STEP Phase 3a trials people without type 2 diabetes lost 17-18% of their body weight on average over 68 weeks.
  3. · Novo Nordisk's SELECT trial: semaglutide cuts major cardiovascular events by 20%
    Headline results from the 17,604-person trial showed semaglutide 2.4 mg lowered the combined risk of cardiovascular death, non-fatal heart attack and non-fatal stroke by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease.
  4. · FDA approves Eli Lilly's tirzepatide as Zepbound for chronic weight management
    The FDA approved Eli Lilly's tirzepatide, sold as Zepbound, for weight management in adults with obesity or overweight. The drug was already sold as Mounjaro for type 2 diabetes, so the approval let Lilly sell it for weight loss too. In trials, people on the highest dose lost about 18% of their body weight.

Assets named in this scenario · 21

AlconAstraZenecaBayerChugai PharmaceuticalDaiichi SankyoFreseniusGrifolsGSKiShares Biotechnology ETFJohnson & JohnsonLilly (Eli)LonzaMerck KGaANovartisNovo Nordisk (ADR)PfizerSanofiSiemens HealthineersSPDR S&P Biotech ETFTakeda PharmaceuticalTerumo

Recently triggered by news

Matched keywords: fda approval, drug trial results, obesity drug, glp-1, clinical trial, breakthrough therapy, drug pricing, cancer vaccine, late-stage trial, phase 3 results, oncology, immunotherapy, gene therapy, biotech rally, fda onayı, ilaç denemesi, kanser aşısı, faz 3

See how this scenario relates to your assets

Your portfolio, plain-language analyses, price alerts and the AIsier chat, together on your phone.

Get it on Google Play
App Store: coming soonContinue on the web

Free to download. AI analyses use credits; the app shows the cost before you start.

AIsier does not give investment advice. Every figure on this page is a measurement of past prices or a quote from a named source, never a recommendation to buy, sell or hold.